EP Wealth Advisors LLC Makes New Investment in Krystal Biotech, Inc. $KRYS

Key Points

• EP Wealth Advisors LLC acquired a new position in Krystal Biotech, purchasing 2,621 shares valued at approximately $473,000 during the first quarter.
• Insider Suma Krishnan sold 1,389 shares of Krystal Biotech, decreasing their ownership stake by 0.09%; insiders have sold a total of 49,800 shares worth $7.5 million over the last quarter.
• Krystal Biotech reported $1.29 EPS for the last quarter, exceeding analysts' expectations, and has a current consensus rating of "Moderate Buy" with a target price of $210.38.

EP Wealth Advisors LLC purchased a new stake in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 2,621 shares of the company's stock, valued at approximately $473,000.

Several other large investors have also recently added to or reduced their stakes in KRYS. Nuveen LLC acquired a new position in Krystal Biotech in the 1st quarter valued at approximately $42,223,000. Braidwell LP raised its holdings in Krystal Biotech by 99.9% in the 1st quarter. Braidwell LP now owns 400,744 shares of the company's stock valued at $72,254,000 after acquiring an additional 200,244 shares in the last quarter. T. Rowe Price Investment Management Inc. acquired a new position in Krystal Biotech in the 1st quarter valued at approximately $33,455,000. Soleus Capital Management L.P. raised its holdings in Krystal Biotech by 65.2% in the 4th quarter. Soleus Capital Management L.P. now owns 358,379 shares of the company's stock valued at $56,144,000 after acquiring an additional 141,400 shares in the last quarter. Finally, 1832 Asset Management L.P. acquired a new position in Krystal Biotech in the 1st quarter valued at approximately $24,521,000. Institutional investors and hedge funds own 86.29% of the company's stock.

Insider Transactions at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 13,435 shares of the company's stock in a transaction on Monday, July 14th. The stock was sold at an average price of $150.30, for a total transaction of $2,019,280.50. Following the transaction, the insider owned 1,443,276 shares of the company's stock, valued at approximately $216,924,382.80. This represents a 0.92% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last 90 days, insiders sold 49,800 shares of company stock worth $7,487,943. 13.70% of the stock is currently owned by corporate insiders.

Krystal Biotech Trading Up 3.6%

NASDAQ KRYS traded up $4.92 during trading hours on Thursday, reaching $142.38. 118,687 shares of the company's stock were exchanged, compared to its average volume of 326,093. The stock has a market cap of $4.12 billion, a PE ratio of 28.94 and a beta of 0.66. Krystal Biotech, Inc. has a one year low of $122.80 and a one year high of $207.84. The firm has a fifty day moving average of $146.77 and a 200-day moving average of $153.30.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its quarterly earnings data on Monday, August 4th. The company reported $1.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.08 by $0.21. Krystal Biotech had a return on equity of 15.21% and a net margin of 40.85%.The firm had revenue of $96.04 million for the quarter, compared to the consensus estimate of $95.42 million. As a group, research analysts forecast that Krystal Biotech, Inc. will post 6.14 EPS for the current year.

Analyst Ratings Changes

Several research firms have recently weighed in on KRYS. Bank of America lowered their price objective on Krystal Biotech from $193.00 to $192.00 and set a "buy" rating on the stock in a research note on Tuesday, July 22nd. HC Wainwright reiterated a "buy" rating and issued a $240.00 price objective on shares of Krystal Biotech in a research note on Friday, August 22nd. Citigroup reiterated a "neutral" rating and issued a $166.00 price objective (down from $176.00) on shares of Krystal Biotech in a research note on Tuesday, August 5th. Finally, Chardan Capital lowered their price objective on Krystal Biotech from $219.00 to $216.00 and set a "buy" rating on the stock in a research note on Friday, August 22nd. Six research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $209.00.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).